LSMO-01 - Novel antimicrobials in the pipeline and the use of computational medicinal chemistry in finding new antimicrobial agents
Tracks
Room A1
| Monday, September 1, 2025 |
| 13:00 - 14:00 |
| Room A1 |
Details
Chair(s)
MSc.Pharm Peter Thøgersen, Pharmadanmark, Denmark & Prof. Giovanni Pauletti, FIP Board of Pharmaceutical Sciences, USA
Introduction:
As antimicrobial resistance continues to challenge the effectiveness of existing treatments, the search for novel antimicrobial agents is gaining momentum. Advances in areas such as gene editing and computational medicinal chemistry are supporting innovative approaches to drug discovery. This session will explore the potential of CRISPR technology in targeting infectious diseases and examine scientific and practical considerations in developing the next generation of antibiotics. Through examples from research and industry, the session will consider how these tools are being applied to expand the antimicrobial pipeline.
Programme:
Learning objectives
1. Explore scientific approaches to antimicrobial drug discovery, including gene editing technologies and computational tools.
2. Understand key challenges and opportunities in developing next-generation antibiotics.
3. Consider how research and industry are contributing to the expansion of the antimicrobial pipeline through innovative methods.
Take home messages
Advancing the development of novel antimicrobial agents requires a combination of innovative scientific approaches, cross-sector collaboration, and sustained investment to address the growing threat of antimicrobial resistance.
FIP Development Goals
To learn more about these FIP Development Goals, click on the links below.
FIP Development Goal 17: Antimicrobial Stewardship
FIP Development Goal 18: Access to Medicines, Devices & Services
FIP Development Goal 19: Patient Safety
| 13:00 – 13:05 | Introduction by the chairs | |
| 13:05 – 13:30 | The use of clustered regularly interspaced short palindromic repeats (CRISPR) technology in developing novel treatments against infection diseases | |
| Dr Christian Grøndahl, SNIPR Biome, Denmark | ||
| 13:30 – 13:55 | Developing the next generation antibiotics – challenges and opportunities | |
| Prof. Anders Karlén, Uppsala University, Sweden | ||
| 13:55 – 14:00 | Closing by the chairs |
Speakers
Dr Christian Grøndahl
SNIPR Biome
SNIPR BIOME: CRISPR-based microbial gene therapies to address antimicrobial resistance, metabolic disorders, and immune conditions
